| 摘要 |
<p>The present invention is based, in part, on the discovery that febrile responses and transfusion immunomodulaton can occur in patients who have received platelets and, further, that these adverse effects are due to CD40 ligand (CD40L; also known as CD154) presentation and release (e.g. relaease during the collection, centrigugation, and storage of platelets or other CD40L-bearing cells or substances). Accordingly, the invention features compositions and methods for reducing the risk that patients who receive platelets (or other DC40L-bearing cells or substances) will experience an adverse reaction. The invention also features methods for diagnosing an adverse response in a patient receiving a transfusion. In addition, the invention features compositions and methods of immunotherapy through modulation of a patient's immune response.</p> |
